ATE333888T1 - Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen - Google Patents
Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungenInfo
- Publication number
- ATE333888T1 ATE333888T1 AT01970886T AT01970886T ATE333888T1 AT E333888 T1 ATE333888 T1 AT E333888T1 AT 01970886 T AT01970886 T AT 01970886T AT 01970886 T AT01970886 T AT 01970886T AT E333888 T1 ATE333888 T1 AT E333888T1
- Authority
- AT
- Austria
- Prior art keywords
- inflammation
- treatment
- extracellular domain
- polypeptide containing
- seq
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101001044895 Homo sapiens Interleukin-20 receptor subunit beta Proteins 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 102100022706 Interleukin-20 receptor subunit alpha Human genes 0.000 title 1
- 101710174006 Interleukin-20 receptor subunit alpha Proteins 0.000 title 1
- 102100022705 Interleukin-20 receptor subunit beta Human genes 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23330500P | 2000-09-15 | 2000-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE333888T1 true ATE333888T1 (de) | 2006-08-15 |
Family
ID=22876714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05028379T ATE460429T1 (de) | 2000-09-15 | 2001-09-13 | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb |
| AT01970886T ATE333888T1 (de) | 2000-09-15 | 2001-09-13 | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05028379T ATE460429T1 (de) | 2000-09-15 | 2001-09-13 | Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7855269B2 (de) |
| EP (2) | EP1803733B1 (de) |
| JP (1) | JP4908723B2 (de) |
| AT (2) | ATE460429T1 (de) |
| AU (1) | AU2001290837A1 (de) |
| CA (1) | CA2422033A1 (de) |
| DE (2) | DE60121808T2 (de) |
| DK (1) | DK1351703T3 (de) |
| ES (1) | ES2267814T3 (de) |
| WO (1) | WO2002022153A2 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965704A (en) * | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| ATE342980T1 (de) * | 2000-08-08 | 2006-11-15 | Zymogenetics Inc | Lösliche zcyctor 11 cytokinrezeptoren |
| US7855269B2 (en) * | 2000-09-15 | 2010-12-21 | Zymogenetics, Inc. | Method for treating inflammation |
| DE602004028347D1 (de) * | 2003-03-24 | 2010-09-09 | Zymogenetics Inc | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung |
| US20040248097A1 (en) * | 2003-05-23 | 2004-12-09 | Ming-Shi Chang | Interleukin-20 variants and promoters |
| EP2087905A2 (de) | 2003-08-08 | 2009-08-12 | Novo Nordisk A/S | Interleukin-20 zur Behandlung und Diagnose von mit Neovaskularization verbunden Zuständen |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| EP1697418A2 (de) * | 2003-11-21 | 2006-09-06 | ZymoGenetics, Inc. | Anti-il-20-rezeptor-antikörper und bindungspartner und verfahren zur anwendung bei entzündungen |
| KR101200133B1 (ko) | 2004-06-01 | 2012-11-13 | 제넨테크, 인크. | 항체 약물 접합체 및 방법 |
| EP1791565B1 (de) | 2004-09-23 | 2016-04-20 | Genentech, Inc. | Zystein-modifizierte Antikörper und Konjugate |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| EA015706B1 (ru) | 2004-10-22 | 2011-10-31 | Займоджинетикс, Инк. | Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела |
| AU2006212807A1 (en) * | 2005-02-08 | 2006-08-17 | Zymogenetics, Inc. | Anti-IL-20, anti-IL-22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| EP2035452B1 (de) | 2006-06-22 | 2012-04-25 | Novo Nordisk A/S | Lösliche heterodimere rezeptoren und ihre verwendung |
| WO2011031870A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| PH12012501836A1 (en) | 2010-04-15 | 2013-02-04 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| KR101839163B1 (ko) | 2010-06-08 | 2018-03-15 | 제넨테크, 인크. | 시스테인 조작된 항체 및 접합체 |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| CA2833212C (en) | 2011-05-12 | 2020-06-09 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides |
| EA026827B1 (ru) | 2011-10-14 | 2017-05-31 | Медимьюн Лимитед | Пирролбензодиазепины и их конъюгаты |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| LT2906296T (lt) | 2012-10-12 | 2018-06-11 | Adc Therapeutics Sa | Pirolobenzodiazepino-antikūno konjugatai |
| WO2014057114A1 (en) | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sàrl | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| CA2885340C (en) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| HUE042731T2 (hu) | 2012-10-12 | 2019-07-29 | Adc Therapeutics Sa | Pirrolobenzodiazepin-antitest konjugátumok |
| RS56520B1 (sr) | 2012-10-12 | 2018-02-28 | Adc Therapeutics Sa | Pirolobenzodiazepin-anti-cd22 konjugati antitela |
| US10751346B2 (en) | 2012-10-12 | 2020-08-25 | Medimmune Limited | Pyrrolobenzodiazepine—anti-PSMA antibody conjugates |
| ES2660029T3 (es) | 2012-10-12 | 2018-03-20 | Medimmune Limited | Conjugados de anticuerpo-pirrolobenzodiazepinas |
| EP2935273A1 (de) | 2012-12-21 | 2015-10-28 | MedImmune Limited | Asymmetrische pyrrolobenzodiazepin-dimere zur verwendung bei der behandlung von proliferativen und autoimmunerkrankungen |
| US9562049B2 (en) | 2012-12-21 | 2017-02-07 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| KR102066319B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| KR102066318B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
| EP3033111B1 (de) | 2013-08-12 | 2019-03-13 | Genentech, Inc. | 1-(chlormethyl) 2,3-dihydro-1h-benzo[e]indoldimer-antikörper-wirkstoff-konjugatverbindungen und verfahren zur verwendung und behandlung |
| EP3054986B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| US10010624B2 (en) | 2013-10-11 | 2018-07-03 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| KR102354207B1 (ko) | 2013-12-16 | 2022-01-20 | 제넨테크, 인크. | 펩티드모방체 화합물 및 그의 항체-약물 접합체 |
| CN105828840B (zh) | 2013-12-16 | 2020-08-04 | 基因泰克公司 | 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法 |
| SG11201604905WA (en) | 2013-12-16 | 2016-07-28 | Genentech Inc | Peptidomimetic compounds and antibody-drug conjugates thereof |
| DK3149049T3 (da) | 2014-05-27 | 2023-01-23 | Univ Queensland | Il-22 til anvendelse til behandling af stofskiftesygdomme |
| EP3151921B1 (de) | 2014-06-06 | 2019-08-28 | Bristol-Myers Squibb Company | Antikörper gegen glucocorticoidinduzierten tumornekrosefaktorrezeptor (gitr) und verwendungen davon |
| CN106687141A (zh) | 2014-09-10 | 2017-05-17 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其缀合物 |
| JP6622293B2 (ja) | 2014-09-12 | 2019-12-18 | ジェネンテック， インコーポレイテッド | アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法 |
| CA2957354A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| CR20170099A (es) | 2014-09-17 | 2017-07-19 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpos-disulfuro de las mismas |
| US10780096B2 (en) | 2014-11-25 | 2020-09-22 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| EP3304079B1 (de) | 2015-06-03 | 2020-06-03 | Bristol-Myers Squibb Company | Anti-gitr-antikörper zur krebsdiagnostik |
| AU2016331931C1 (en) | 2015-10-02 | 2020-01-16 | Genentech, Inc. | Pyrrolobenzodiazepine antibody drug conjugates and methods of use |
| JP6621919B2 (ja) | 2015-10-16 | 2019-12-18 | ジェネンテック， インコーポレイテッド | 束縛ジスルフィド薬物コンジュゲート |
| JP6852065B2 (ja) | 2015-10-20 | 2021-03-31 | ジェネンテック， インコーポレイテッド | カリケアマイシン−抗体−薬物コンジュゲート及び使用方法 |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN121431692A (zh) | 2016-03-25 | 2026-01-30 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| EP3458101B1 (de) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac-antikörper-konjugate und verfahren zur verwendung |
| CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
| JP7043425B2 (ja) | 2016-06-06 | 2022-03-29 | ジェネンテック， インコーポレイテッド | シルベストロール抗体－薬物コンジュゲート及び使用方法 |
| WO2018031662A1 (en) | 2016-08-11 | 2018-02-15 | Genentech, Inc. | Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| HRP20210979T1 (hr) | 2017-02-08 | 2021-09-17 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protutijelo |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| PT3612537T (pt) | 2017-04-18 | 2022-08-29 | Medimmune Ltd | Conjugados de pirrolobenzodiazepina |
| MX2019012464A (es) | 2017-04-20 | 2019-12-11 | Adc Therapeutics Sa | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. |
| US11685787B2 (en) | 2017-05-16 | 2023-06-27 | Bristol-Myers Squibb Company | Treatment of cancer with anti-GITR agonist antibodies |
| BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
| SMT202200225T1 (it) | 2017-08-18 | 2022-07-21 | Medimmune Ltd | Coniugati di pirrolobenzodiazepina |
| WO2019060398A1 (en) | 2017-09-20 | 2019-03-28 | Ph Pharma Co., Ltd. | ANALOGUES OF THAILANSTATINE |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| IL282441B2 (en) | 2018-10-24 | 2025-07-01 | Hoffmann La Roche | Conjugated chemical inducers of degradation and methods of use |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| EP3938372B1 (de) | 2019-03-15 | 2023-10-25 | MedImmune Limited | Azetidobenzodiazepindimere und konjugate damit zur verwendung in der behandlung von krebs |
| JP2024541058A (ja) | 2021-11-03 | 2024-11-06 | ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． | 抗体の特異的共役 |
| CN120417934A (zh) | 2022-12-23 | 2025-08-01 | 基因泰克公司 | Cereblon降解剂缀合物及其用途 |
| CN121263210A (zh) | 2023-04-17 | 2026-01-02 | 沛科生物公司 | 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体 |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5436155A (en) * | 1991-12-31 | 1995-07-25 | Arch Development Corporation | Isolated DNA encoding a somatostatin receptor |
| US5789192A (en) * | 1992-12-10 | 1998-08-04 | Schering Corporation | Mammalian receptors for interleukin-10 (IL-10) |
| US5985614A (en) | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| US5945511A (en) * | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| JP2001510035A (ja) | 1997-07-16 | 2001-07-31 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | インターロイキン−２０ |
| US6486301B1 (en) * | 1997-07-16 | 2002-11-26 | Human Genome Sciences, Inc. | Interleukin-20 |
| US5965704A (en) | 1997-08-05 | 1999-10-12 | Zymogenetics, Inc. | Class two cytokine receptor-11 |
| EP1009762A2 (de) * | 1997-08-06 | 2000-06-21 | ZymoGenetics, Inc. | Lipocalinhomologen |
| US6576743B1 (en) * | 1997-11-26 | 2003-06-10 | Zymogenetics, Inc. | Mammalian cytokine-like polypeptide-10 |
| PL198687B1 (pl) | 1997-11-26 | 2008-07-31 | Zymogenetics Inc | Zastosowanie polipeptydu do wytwarzania leku |
| DK1047781T3 (da) | 1998-01-23 | 2004-12-06 | Immunex Corp | IL-18-receptorer |
| AU2871899A (en) | 1998-03-09 | 1999-09-27 | Schering Corporation | Human receptor proteins; related reagents and methods |
| NZ507435A (en) | 1998-03-10 | 2003-12-19 | Genentech Inc | Novel polypeptides and nucleic acids with homology to cornichon |
| US6982320B2 (en) | 1998-03-19 | 2006-01-03 | Human Genome Sciences, Inc. | Cytokine receptor common gamma chain like |
| WO1999061630A2 (en) | 1998-05-26 | 1999-12-02 | Regeneron Pharmaceuticals, Inc. | Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system |
| NZ510464A (en) | 1998-09-01 | 2004-05-28 | Genentech Inc | Further pro polypeptides and sequences thereof |
| WO2000039161A1 (en) | 1998-12-31 | 2000-07-06 | Millennium Pharmaceuticals, Inc. | Class ii cytokine receptor-like proteins and nucleic acids encoding them |
| WO2000073457A1 (en) | 1999-05-27 | 2000-12-07 | Schering-Corporation | Mammalian interleukin-10 homologs: il-d110 and il-d210 |
| AU2883700A (en) | 1999-06-23 | 2001-01-09 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DE60030769T2 (de) | 1999-12-23 | 2007-10-25 | Zymogenetics, Inc., Seattle | Verfahren zur behandlung von entzündungen |
| US6610286B2 (en) * | 1999-12-23 | 2003-08-26 | Zymogenetics, Inc. | Method for treating inflammation using soluble receptors to interleukin-20 |
| US7122632B2 (en) * | 1999-12-23 | 2006-10-17 | Zymogenetics, Inc. | Soluble Interleukin-20 receptor |
| EP1857466B1 (de) | 1999-12-23 | 2010-10-20 | ZymoGenetics, Inc. | Löslicher Interleukin-20-Rezeptor |
| ATE342980T1 (de) | 2000-08-08 | 2006-11-15 | Zymogenetics Inc | Lösliche zcyctor 11 cytokinrezeptoren |
| US7855269B2 (en) * | 2000-09-15 | 2010-12-21 | Zymogenetics, Inc. | Method for treating inflammation |
| EP1390060A2 (de) | 2001-01-26 | 2004-02-25 | Eli Lilly And Company | Verwendung von lp82 zur behandlung von störungen des körpergewichtes |
| WO2002070001A2 (en) | 2001-02-28 | 2002-09-12 | Eli Lilly And Company | Use of lp82 to treat hematopoietic disorders |
| IL157726A0 (en) | 2001-03-09 | 2004-03-28 | Zymogenetics Inc | Soluble heterodimeric cytokine receptor |
| DE10154579A1 (de) | 2001-11-07 | 2003-05-28 | Medigene Ag | Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen |
| IL161978A0 (en) | 2001-12-17 | 2005-11-20 | Zymogenetics Inc | Method for treating cervical cancer |
| DE602004028347D1 (de) | 2003-03-24 | 2010-09-09 | Zymogenetics Inc | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung |
-
2001
- 2001-09-13 US US09/951,268 patent/US7855269B2/en not_active Expired - Fee Related
- 2001-09-13 AT AT05028379T patent/ATE460429T1/de not_active IP Right Cessation
- 2001-09-13 JP JP2002526403A patent/JP4908723B2/ja not_active Expired - Fee Related
- 2001-09-13 CA CA002422033A patent/CA2422033A1/en not_active Abandoned
- 2001-09-13 DK DK01970886T patent/DK1351703T3/da active
- 2001-09-13 DE DE60121808T patent/DE60121808T2/de not_active Expired - Lifetime
- 2001-09-13 EP EP05028379A patent/EP1803733B1/de not_active Expired - Lifetime
- 2001-09-13 WO PCT/US2001/028557 patent/WO2002022153A2/en not_active Ceased
- 2001-09-13 ES ES01970886T patent/ES2267814T3/es not_active Expired - Lifetime
- 2001-09-13 DE DE60141546T patent/DE60141546D1/de not_active Expired - Lifetime
- 2001-09-13 EP EP01970886A patent/EP1351703B1/de not_active Expired - Lifetime
- 2001-09-13 AT AT01970886T patent/ATE333888T1/de active
- 2001-09-13 AU AU2001290837A patent/AU2001290837A1/en not_active Abandoned
-
2010
- 2010-11-09 US US12/942,302 patent/US20110077207A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1803733A3 (de) | 2007-10-31 |
| US7855269B2 (en) | 2010-12-21 |
| EP1803733A2 (de) | 2007-07-04 |
| DK1351703T3 (da) | 2006-11-27 |
| EP1351703A2 (de) | 2003-10-15 |
| AU2001290837A1 (en) | 2002-03-26 |
| JP4908723B2 (ja) | 2012-04-04 |
| WO2002022153A2 (en) | 2002-03-21 |
| JP2004525074A (ja) | 2004-08-19 |
| EP1803733B1 (de) | 2010-03-10 |
| CA2422033A1 (en) | 2002-03-21 |
| ES2267814T3 (es) | 2007-03-16 |
| DE60121808D1 (de) | 2006-09-07 |
| EP1351703B1 (de) | 2006-07-26 |
| US20020085992A1 (en) | 2002-07-04 |
| DE60141546D1 (de) | 2010-04-22 |
| WO2002022153A3 (en) | 2003-06-19 |
| DE60121808T2 (de) | 2007-03-29 |
| US20110077207A1 (en) | 2011-03-31 |
| ATE460429T1 (de) | 2010-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE333888T1 (de) | Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen | |
| IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
| ATE272650T1 (de) | Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes | |
| DE60023870D1 (de) | Verfahren zur herstellung von 3-aryloxy-3-arylpropylamine und deren zwischenprodukte | |
| ATE262895T1 (de) | Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis | |
| DE60333963D1 (de) | Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität | |
| ATE462006T1 (de) | Isoform des vegfs | |
| ATE428413T1 (de) | Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen | |
| DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
| DE60023860D1 (de) | Verfahren zur herstellung von rekombinanten peptiden | |
| CY2198B1 (en) | 1-Aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists | |
| DE69328549D1 (de) | Für einen humanen serotoninrezeptor (5-ht4b) kodierende dns und ihre verwendung | |
| DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| DK0840792T3 (da) | (S)-hydroxynitrillyase fra Hevea brasiliensis | |
| ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
| DE60329115D1 (de) | Tumorantigenprotein und dessen verwendung | |
| DE69918541D1 (de) | Verwendung von nmda antagonisten zur behandlung des reizkolons | |
| ATE405577T1 (de) | Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung | |
| ATE452903T1 (de) | Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten | |
| ATE244760T1 (de) | Wachtumsfaktor aus der harp-reihe, verfahren zu ihrer herstellung und verwendungen davon | |
| ATE397753T1 (de) | Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung | |
| ATE292970T1 (de) | Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden | |
| ATE198218T1 (de) | Htfiiia gen | |
| ATE307580T1 (de) | Verwendung von eprosartan zur behandlung von isoliertem systolischem bluthochdrucks | |
| EP1533378A3 (de) | tks7, ein tyrosinkinase-substrat-protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1351703 Country of ref document: EP |